A study published in the Molecules journal endorsed the efficacy of pharmaceutical-grade chondroitin for the treatment of osteoarthritis
Bioiberica’s joint healthcare division and heparin business unit participated at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
The Russian pharmaceutical market is growing at a 10 percent annual rate, and is expected to reach 25 Billion Dollars by 2018
Our company was granted “good” qualification within the A Group, the one formed by companies having their own manufacturing and R&D center in Spain
During this event, Bioiberica met with leading firms in the field of cosmetics in order to explore possible collaboration opportunities